{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:17:27Z","timestamp":1762899447426,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"suppl_9","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"DOI":"10.1093\/infdis\/jix432","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T23:11:34Z","timestamp":1504048294000},"page":"S805-S807","source":"Crossref","is-referenced-by-count":11,"title":["The US President\u2019s Emergency Plan for AIDS Relief (PEPFAR) and HIV Drug Resistance: Mitigating Risk, Monitoring Impact"],"prefix":"10.1093","volume":"216","author":[{"given":"Elliot","family":"Raizes","sequence":"first","affiliation":[{"name":"Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Hader","sequence":"additional","affiliation":[{"name":"Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Birx","sequence":"additional","affiliation":[{"name":"Office of the US Global AIDS Coordinator, US Department of State"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"author":"Joint United Nations Programme on HIV\/AIDS","key":"key\n\t\t\t\t20180306121542_CIT0001"},{"key":"key\n\t\t\t\t20180306121542_CIT0002","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijantimicag.2007.01.003","article-title":"HIV resistance and the developing world","volume":"29","author":"Gupta","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180306121542_CIT0003","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180306121542_CIT0004","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ije\/dym104","article-title":"Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis","volume":"36","author":"Arriv\u00e9","year":"2007","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20180306121542_CIT0005","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/infdis\/166.5.1139","article-title":"Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy","volume":"166","author":"Land","year":"1992","journal-title":"J Infect Dis"},{"volume-title":"HIV pretreatment drug resistance in Cameroon; first nationwide study. In: Conference on Retroviruses and Opportunistic Infections","author":"Gaelle","key":"key\n\t\t\t\t20180306121542_CIT0006"},{"volume-title":"HIV drug resistance among adults initiating antiretroviral therapy in Namibia. In: Ninth International AIDS Society Conference on HIV Science","year":"2017","author":"Mutenda","key":"key\n\t\t\t\t20180306121542_CIT0007"},{"volume-title":"HIV drug resistance report","year":"2017","author":"World Health Organization","key":"key\n\t\t\t\t20180306121542_CIT0008"},{"volume-title":"Real progress in the HIV epidemic: PHIA findings from Zimbabwe, Malawi, and Zambia. In: Conference on Retroviruses and Opportunistic Infections","year":"2017","author":"Justman","key":"key\n\t\t\t\t20180306121542_CIT0009"},{"key":"key\n\t\t\t\t20180306121542_CIT0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jac\/dkw463","article-title":"Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis","volume":"72","author":"Boerma","year":"2017","journal-title":"J Antimicrob Chemother"},{"volume-title":"Eliminating drug resistance in South Africa by using dolutegravir. Conference on Retroviruses and Opportunistic Infections","year":"2017","author":"Sharp","key":"key\n\t\t\t\t20180306121542_CIT0011"},{"key":"key\n\t\t\t\t20180306121542_CIT0012","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/jac\/dkx042","article-title":"Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies\/mL: a 2014 French nationwide study","volume":"72","author":"Assoumou","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306121542_CIT0013","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"TenoRes Study Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180306121542_CIT0014","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180306121542_CIT0015","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa","volume":"71","author":"Boender","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306121542_CIT0016","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/QAI.0000000000001285","article-title":"HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa","volume":"75","author":"Kityo","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180306121542_CIT0017","article-title":"Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance","author":"Brenner","year":"2016","journal-title":"Virus Res"},{"key":"key\n\t\t\t\t20180306121542_CIT0018","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE Randomized Clinical Trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180306121542_CIT0019","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"volume-title":"ARV market report: the state of the antiretroviral drug market in low- and middle-income countries, 2015\u20132020","author":"Clinton Health Access Initiative","key":"key\n\t\t\t\t20180306121542_CIT0020"},{"volume-title":"Cost-effectiveness of policy options when pretreatment NNRTI drug resistance is high. In: Conference on Retroviruses and Opportunistic Infections","year":"2017","author":"Phillips","key":"key\n\t\t\t\t20180306121542_CIT0021"},{"key":"key\n\t\t\t\t20180306121542_CIT0022","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1468-1293.2006.00404.x","article-title":"Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903","volume":"7","author":"Margot","year":"2006","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180306121542_CIT0023","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/jac\/dku058","article-title":"Has the time come to abandon efavirenz for first-line antiretroviral therapy?","volume":"69","author":"Raffi","year":"2014","journal-title":"J Antimicrob Chemother"},{"author":"World Health Organization","key":"key\n\t\t\t\t20180306121542_CIT0024"},{"key":"key\n\t\t\t\t20180306121542_CIT0025","doi-asserted-by":"crossref","first-page":"e0145772","DOI":"10.1371\/journal.pone.0145772","article-title":"HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing","volume":"10","author":"Rhee","year":"2015","journal-title":"PLoS One"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/suppl_9\/S805\/24264830\/jix432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T12:16:17Z","timestamp":1520338577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/216\/suppl_9\/S805\/4460024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":25,"journal-issue":{"issue":"suppl_9","published-online":{"date-parts":[[2017,10,12]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix432","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2017,11,15]]},"published":{"date-parts":[[2017,10,12]]}}}